EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Efficacy and Safety of Maintenance Therapy Using Cetuximab in Patients with Metastatic Colorectal Cancer: Retrospective Study

Tiantian Xuan, Zhanmei Wang, Sibo Meng iD, Jiaxin Li, Jisheng Li, Fangli Cao, Linli Qu

Cancer Management and Research · 2024-03 · Volume 16 · 185-197

DOI: 10.2147/cmar.s443666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Management and Research, 2024-03. Verfasst von Tiantian Xuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, People's Republic of Ch…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cetuximab (CET) combined with chemotherapy significantly improved the survival in RAS and RAF wild-type metastatic colorectal cancer (mCRC) patients, while clinical evidence was lacking on the use of maintenance therapy (MT). The study aimed to explore the role of maintenance therapy following Cetuximab + chemotherapy and the optimal Cetuximab-based maintenance therapy regimen. Patients and Methods: We retrospectively reviewed data on the efficacy and safety of CET-based MT in patients with mCRC who achieved disease control after induction therapy.

Results

Eighty-one patients with mCRC who achieved disease control after CET + chemotherapy induction were enrolled. Overall median progression-free survival (PFS) was 10.5 (95% CI = 8.8-12.2) months and median maintenance/observation PFS (mnPFS) was 6.0 (95% CI = 5.0-7.0) months. Among these 81 patients, 61 patients were prescribed MT (CET alone for 21 patients and CET + chemotherapy for 40 patients). Median PFS and mnPFS in the MT group were significantly longer than those for the non-MT group. Different MT regimens did not affect PFS and mnPFS significantly. Univariate and multivariate analysis demonstrated MT, complete response/partial response during induction therapy, and absence of peritoneal metastasis to be positively associated with longer PFS and mnPFS. Treatment-related adverse events (AEs) were tolerable during MT, and AE-related deaths were not observed.

Conclusion

MT with CET or CET + chemotherapy was an appropriate option following initial induction chemotherapy for patients with RAS and RAF wild-type mCRC. This strategy endowed survival benefits and a tolerable safety profile.

Schlagwörter

Stichwörter der Autor:innen

RAS and RAF wild-typecetuximabcolorectal cancermaintenance therapytargeted therapy

Autor:innen und Institutionen

  • Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
  • Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China.

ORCID-Profile: Sibo Meng

Zitieren

APA

Xuan, T., Wang, Z., Meng, S., Li, J., Li, J., Cao, F., & Qu, L. (2024). Efficacy and Safety of Maintenance Therapy Using Cetuximab in Patients with Metastatic Colorectal Cancer: Retrospective Study. Cancer Management and Research, Volume 16, 185-197. https://doi.org/10.2147/cmar.s443666

Vancouver

Xuan T, Wang Z, Meng S, Li J, Li J, Cao F, et al. Efficacy and Safety of Maintenance Therapy Using Cetuximab in Patients with Metastatic Colorectal Cancer: Retrospective Study. Cancer Management and Research. 2024;Volume 16:185-197. doi:10.2147/cmar.s443666

BibTeX
@article{Xuan2024,
  author = {Xuan, Tiantian and Wang, Zhanmei and Meng, Sibo and Li, Jiaxin and Li, Jisheng and Cao, Fangli and Qu, Linli},
  title = {Efficacy and Safety of Maintenance Therapy Using Cetuximab in Patients with Metastatic Colorectal Cancer: Retrospective Study},
  journal = {Cancer Management and Research},
  year = {2024},
  volume = {Volume 16},
  pages = {185--197},
  doi = {10.2147/cmar.s443666}
}
Kostenlos starten →